Suppr超能文献

阿普坦西奥XR(盐酸哌甲酯缓释)胶囊对注意力缺陷/多动障碍儿童睡眠的影响。

Effect of Aptensio XR (Methylphenidate HCl Extended-Release) Capsules on Sleep in Children with Attention-Deficit/Hyperactivity Disorder.

作者信息

Owens Judith, Weiss Margaret, Nordbrock Earl, Mattingly Greg, Wigal Sharon, Greenhill Laurence L, Chang Wei-Wei, Childress Ann, Kupper Robert J, Adjei Akwete

机构信息

1 Boston Children's Hospital , Harvard Medical School, Boston, Massachusetts.

2 Division of Child Psychiatry, British Columbia's Children's Hospital, University of British Columbia Medical Center , Vancouver, British Columbia, Canada .

出版信息

J Child Adolesc Psychopharmacol. 2016 Dec;26(10):873-881. doi: 10.1089/cap.2016.0083. Epub 2016 Oct 18.

Abstract

OBJECTIVE

To evaluate measures of sleep (exploratory endpoints) in two pivotal studies of a multilayer bead extended-release methylphenidate (MPH-MLR) treatment of attention-deficit/hyperactivity disorder in children.

METHODS

Study 1 evaluated the time course of response to MPH-MLR (n = 26) patients in an analog classroom setting through four phases: screening (≤28 days), open label (OL) dose optimization (4 weeks), double-blind (DB) crossover (2 weeks; placebo vs. optimized dose), and follow-up call. Study 2 was a forced-dose parallel evaluation of MPH-MLR (n = 230) in four phases: screening (≤28 days), DB (1 week; placebo or MPH-MLR 10, 15, 20, or 40 mg/day), OL dose optimization (11 weeks), and follow-up call. Sleep was evaluated by parents using the Children's or Adolescent Sleep Habits Questionnaire (CSHQ or ASHQ) during the DB and OL phases. DB analysis: Study 1 (crossover), analysis of variance; Study 2, analysis of covariance. OL analysis: paired t-test.

RESULTS

DB: treatments were significantly different in Study 1 only for CSHQ Sleep Onset Delay (MPH-MLR, 1.90 vs. placebo, 1.34; p = 0.0046, placebo was better), and Study 2 for CSHQ Parasomnias (treatment, p = 0.0295), but no MPH-MLR treatment was different from placebo (pairwise MPH-MLR treatment to placebo, all p ≥ 0.170). OL: CSHQ total and Bedtime Resistance, Sleep Duration, Sleep Anxiety, Night Wakings, Parasomnias, and Sleep-disordered Breathing subscales decreased (improved, Study 1) significant only for CSHQ Night Wakings (p < 0.05); in Study 2 CSHQ total and Bedtime Resistance, Sleep Duration, Night Wakings, Parasomnias, and Daytime Sleepiness, and ASHQ total, Bedtime, Sleep Behavior, and Morning Waking all significantly improved (p < 0.05).

CONCLUSIONS

In both studies, there was minimal negative impact of MPH-MLR on sleep during the brief DB phase and none during the longer duration OL phase. Some measures of sleep improved with optimized MPH-MLR dose.

摘要

目的

在两项关于多层珠缓释哌甲酯(MPH-MLR)治疗儿童注意力缺陷多动障碍的关键研究中,评估睡眠指标(探索性终点)。

方法

研究1在模拟课堂环境中评估了MPH-MLR(n = 26)患者的反应时间过程,分为四个阶段:筛查(≤28天)、开放标签(OL)剂量优化(4周)、双盲(DB)交叉(2周;安慰剂与优化剂量)以及随访电话。研究2是对MPH-MLR(n = 230)进行的强制剂量平行评估,分为四个阶段:筛查(≤28天)、双盲(1周;安慰剂或MPH-MLR 10、15、20或40毫克/天)、开放标签剂量优化(11周)以及随访电话。在双盲和开放标签阶段,由家长使用儿童或青少年睡眠习惯问卷(CSHQ或ASHQ)对睡眠进行评估。双盲分析:研究1(交叉),方差分析;研究2,协方差分析。开放标签分析:配对t检验。

结果

双盲阶段:仅在研究1中,治疗组在CSHQ睡眠起始延迟方面存在显著差异(MPH-MLR为1.90,安慰剂为1.34;p = 0.0046,安慰剂更好);在研究2中,治疗组在CSHQ异态睡眠方面存在显著差异(治疗,p = 0.0295),但没有MPH-MLR治疗组与安慰剂组存在差异(MPH-MLR治疗组与安慰剂组两两比较,所有p≥0.170)。开放标签阶段:CSHQ总分以及上床睡觉抗拒、睡眠时间、睡眠焦虑、夜间觉醒、异态睡眠和睡眠呼吸障碍分量表有所下降(改善,研究1),仅CSHQ夜间觉醒有显著下降(p < 0.05);在研究2中,CSHQ总分以及上床睡觉抗拒、睡眠时间、夜间觉醒、异态睡眠和日间嗜睡,以及ASHQ总分、上床睡觉、睡眠行为和早晨醒来均有显著改善(p < 0.05)。

结论

在两项研究中,在短暂的双盲阶段,MPH-MLR对睡眠的负面影响极小,在较长时间的开放标签阶段则没有负面影响。随着MPH-MLR剂量的优化,一些睡眠指标有所改善。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/847f/5178023/169d526edd3c/fig-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验